Treatment of Mental Disorders in Patients with Parkinson's Disease

被引:1
作者
Meincke, U. [1 ,2 ]
Kosinski, C. M. [3 ]
机构
[1] Univ Duisburg Essen, Klin Psychiat & Psychotherapie, Klinikum Niederberg, Lehrkrankenhaus, D-42549 Velbert, Germany
[2] Rhein Westfal TH Aachen, Univ Klinikum, Klin Psychiat & Psychotherapie, Aachen, Germany
[3] Rhein Westfal TH Aachen, Lehrkrankenhaus, Med Zentrum Kreis Aachen gGmbH, Neurol Klin, Aachen, Germany
关键词
dementia; depression; Parkinson's disease; psychosis; DEEP-BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION; IMPULSE CONTROL DISORDERS; DOUBLE-BLIND; VISUAL HALLUCINATIONS; MOTOR FUNCTION; PSYCHOTIC SYMPTOMS; NONMOTOR SYMPTOMS; MAJOR DEPRESSION; CONTROLLED-TRIAL;
D O I
10.1055/s-0029-1245307
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Patients with Parkinson's disease (PD) have a high risk of psychiatric complications, like depressive or psychotic syndromes, dementia and sleep disorders. Although these disorders may even precede the onset of motor symptoms, they are often not recognized and therefore not adequately treated. This article provides a comprehensive overview of the therapeutic options of the most commonly observed psychopathological syndromes in PD. In the case of depressive syndromes medication could be optimized by making use of dopamine agonists that have been proven to have antidepressant properties. In recent studies tricyclic antidepressants showed stronger effects than SSRI. Psychotic symptoms are most often evoked by dopaminergic therapy or are seen in the course of cognitive decline. The therapeutic regimen should be built mainly on L-Dopa medication in the lowest tolerated dose, if required in combinations with COMT-Inhibitors. When antipsychotic medication is indicated, clozapine is the first choice. Quetiapine might also be useful in many patients. Psychotic symptoms in demented patients may respond to Cholinesterase-Inhibitors, that also delay cognitive decline. Patients with PD require an individually optimized therapeutic regimen not only for motor symptoms, but also for frequently occurring psychiatric syndromes since these strongly influence the patients' and their caregivers' quality of life, are predictors for hospitalization and therefore have great economic importance for health care systems.
引用
收藏
页码:279 / 287
页数:9
相关论文
共 135 条
[1]   Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study [J].
Aarsland, D ;
Larsen, JP ;
Tandberg, E ;
Laake, K .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) :938-942
[2]   Frequency of dementia in Parkinson disease [J].
Aarsland, D ;
Tandberg, E ;
Larsen, JP ;
Cummings, JL .
ARCHIVES OF NEUROLOGY, 1996, 53 (06) :538-542
[3]  
ANDERSEN J, 1980, ACTA NEUROL SCAND, V62, P210
[4]  
[Anonymous], 1997, Ann Neurol, V42, P747
[5]  
[Anonymous], LEITLINIEN DIAGNOSTI
[6]   Hallucinations, REM sleep, and Parkinson's disease - A medical hypothesis [J].
Arnulf, I ;
Bonnet, AM ;
Damier, P ;
Bejjani, BP ;
Seilhean, D ;
Derenne, JP ;
Agid, Y .
NEUROLOGY, 2000, 55 (02) :281-288
[7]   Pramipexole versus sertraline in the treatment of depression in Parkinson's disease - A national multicenter parallel-group randomized study [J].
Barone, Paolo ;
Scarzella, Leonardo ;
Marconi, Roberto ;
Antonini, Angelo ;
Morgante, Letterio ;
Bracco, Fulvio ;
Zappia, Mario ;
Musch, Bruno .
JOURNAL OF NEUROLOGY, 2006, 253 (05) :601-607
[8]   Effect on mood of subthalamic DBS for Parkinson's disease - A consecutive series of 24 patients [J].
Berney, A ;
Vingerhoets, F ;
Perrin, A ;
Phil, L ;
Guex, P ;
Villemure, JG ;
Burkhard, PR ;
Benkelfat, C ;
Ghika, J .
NEUROLOGY, 2002, 59 (09) :1427-1429
[9]   Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease - An in vivo positron emission tomographic study [J].
Bohnen, NI ;
Kaufer, DI ;
Ivanco, LS ;
Lopresti, B ;
Koeppe, RA ;
Davis, JG ;
Mathis, CA ;
Moore, RY ;
DeKosky, ST .
ARCHIVES OF NEUROLOGY, 2003, 60 (12) :1745-1748
[10]   Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease [J].
Breier, A ;
Sutton, VK ;
Feldman, PD ;
Kadam, DL ;
Ferchland, I ;
Wright, P ;
Friedman, JH .
BIOLOGICAL PSYCHIATRY, 2002, 52 (05) :438-445